- Secures regulatory approval for V-Laser in Vietnam, reinforcing its position in a key market and establishing an early foothold in a high-growth region
- Receives approval from Vietnam’s Ministry of Health for broad clinical applications, including use across dermatology, general surgery, and plastic surgery
- Accelerates market entry through its existing distributor network following strong interest from local physicians during the V-Laser introductory webinar
(February 10, 2026) WONTECH Co., Ltd. (KOSDAQ: 336570), a laser and energy-based medical solutions company led by CEOs Kim Jong-won and Kim Jung-hyun, has obtained regulatory approval for its V-Laser device in Vietnam, accelerating its expansion into the Southeast Asian medical aesthetics market.
With this approval, WONTECH has expanded its product lineup in Vietnam to include V-Laser, following Oligio and Oligio X, further strengthening its position in one of Southeast Asia’s key markets. Securing consecutive regulatory approvals despite stringent certification standards not only validates the company’s technological competitiveness but also represents a strategic move to establish an early foothold in a high-growth market.
Vietnam’s Ministry of Health (MOH) approved V-Laser as a medical device, recognizing its broad clinical applicability. Utilizing dual wavelengths of 1064 nm and 532 nm, the device can be used for a wide range of indications, including telangiectasia, freckles, melasma, dark circles, warts, pigmented lesions, hair removal, and skin tightening. The system is also considered suitable for diverse clinical settings, including dermatology, general surgery, and plastic surgery, for both surgical and aesthetic procedures.
V-Laser is gaining recognition in the industry as a next-generation solution that advances beyond conventional vascular and pigment lasers. Its dual-wavelength technology combined with a precise energy control system enhances treatment efficacy while reducing post-procedure recovery time. These advantages have been well received by physicians and have contributed to its growing competitiveness in the global market.
WONTECH has already established a stable network with local physicians by supplying radiofrequency and laser devices in the Vietnamese market. With the approval of V-Laser, the company has now expanded its product portfolio into vascular and pigment treatment solutions, enabling local clinics to offer a wider range of procedures.
Vietnam is considered one of the leading drivers of the Southeast Asian medical aesthetics market, supported by a population of approximately 100 million and a large young consumer base. According to market research firm IMARC Group, the country’s medical aesthetics market is projected to grow from $91.5 million in 2024 to $188.41 million by 2033, more than doubling over the period.
A WONTECH official stated, “We have already seen strong interest from local physicians, with more than 100 Vietnamese doctors participating in our recent V-Laser introduction and clinical case webinar.” The official added that the company plans to accelerate market penetration by leveraging its existing distributor network to secure both rapid entry and a stable sales foundation.
The official further noted, “With regulatory approvals already secured in 12 countries worldwide, V-Laser has demonstrated its global competitiveness. We will continue to strengthen our global expansion through market-specific strategies tailored to each region.”
- Receives approval from Vietnam’s Ministry of Health for broad clinical applications, including use across dermatology, general surgery, and plastic surgery
- Accelerates market entry through its existing distributor network following strong interest from local physicians during the V-Laser introductory webinar
▲ V-Laser Product Image
(February 10, 2026) WONTECH Co., Ltd. (KOSDAQ: 336570), a laser and energy-based medical solutions company led by CEOs Kim Jong-won and Kim Jung-hyun, has obtained regulatory approval for its V-Laser device in Vietnam, accelerating its expansion into the Southeast Asian medical aesthetics market.
With this approval, WONTECH has expanded its product lineup in Vietnam to include V-Laser, following Oligio and Oligio X, further strengthening its position in one of Southeast Asia’s key markets. Securing consecutive regulatory approvals despite stringent certification standards not only validates the company’s technological competitiveness but also represents a strategic move to establish an early foothold in a high-growth market.
Vietnam’s Ministry of Health (MOH) approved V-Laser as a medical device, recognizing its broad clinical applicability. Utilizing dual wavelengths of 1064 nm and 532 nm, the device can be used for a wide range of indications, including telangiectasia, freckles, melasma, dark circles, warts, pigmented lesions, hair removal, and skin tightening. The system is also considered suitable for diverse clinical settings, including dermatology, general surgery, and plastic surgery, for both surgical and aesthetic procedures.
V-Laser is gaining recognition in the industry as a next-generation solution that advances beyond conventional vascular and pigment lasers. Its dual-wavelength technology combined with a precise energy control system enhances treatment efficacy while reducing post-procedure recovery time. These advantages have been well received by physicians and have contributed to its growing competitiveness in the global market.
WONTECH has already established a stable network with local physicians by supplying radiofrequency and laser devices in the Vietnamese market. With the approval of V-Laser, the company has now expanded its product portfolio into vascular and pigment treatment solutions, enabling local clinics to offer a wider range of procedures.
Vietnam is considered one of the leading drivers of the Southeast Asian medical aesthetics market, supported by a population of approximately 100 million and a large young consumer base. According to market research firm IMARC Group, the country’s medical aesthetics market is projected to grow from $91.5 million in 2024 to $188.41 million by 2033, more than doubling over the period.
A WONTECH official stated, “We have already seen strong interest from local physicians, with more than 100 Vietnamese doctors participating in our recent V-Laser introduction and clinical case webinar.” The official added that the company plans to accelerate market penetration by leveraging its existing distributor network to secure both rapid entry and a stable sales foundation.
The official further noted, “With regulatory approvals already secured in 12 countries worldwide, V-Laser has demonstrated its global competitiveness. We will continue to strengthen our global expansion through market-specific strategies tailored to each region.”